Evidence map›Paper›PMID 34206051›Full record

ArticleInternational journal of molecular sciences2021

Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.

Inken Salewski, Julia Henne, Leonie Engster, Bjoern Schneider, Heiko Lemcke, Anna Skorska, Peggy Berlin, Larissa Henze, Christian Junghanss, Claudia Maletzki

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Inken SalewskiDepartment of Medicine, Clinic III-Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany.
Julia HenneDepartment of Medicine, Clinic III-Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany.
Leonie EngsterDepartment of Medicine, Clinic III-Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany.
Bjoern SchneiderInstitute of Pathology, Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany.ORCID 0000-0002-0282-7330
Heiko LemckeDepartment of Cardiac Surgery, Reference and Translation Center for Cardiac Stem Cell Therapy (RTC), Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany.ORCID 0000-0003-2821-2323
Anna SkorskaDepartment of Cardiac Surgery, Reference and Translation Center for Cardiac Stem Cell Therapy (RTC), Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany.ORCID 0000-0001-6287-4916
Peggy BerlinDivision of Gastroenterology and Endocrinology, Department of Medicine II, Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany.ORCID 0000-0001-8354-6970
Larissa HenzeDepartment of Medicine, Clinic III-Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany.
Christian JunghanssDepartment of Medicine, Clinic III-Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany.
Claudia MaletzkiDepartment of Medicine, Clinic III-Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany.ORCID 0000-0002-8389-8439
University of Rostock · DE

Funding

Deutsche Forschungsgemeinschaft MA5799/2-2
6 · The paper itself

Abstract

Tumors arising in the context of Lynch Syndrome or constitutional mismatch repair deficiency are hypermutated and have a good response towards immune-checkpoint inhibitors (ICIs), including α-PD-L1 antibodies. However, in most cases, resistance mechanisms evolve. To improve outcomes and prevent resistance development, combination approaches are warranted. Herein, we applied a combined regimen with an α-PD-L1 antibody and gemcitabine in a preclinical tumor model to activate endogenous antitumor immune responses. Mlh1

Indexed as

AnimalsB7-H1 AntigenBrain NeoplasmsChemokine CCL4Colorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisDeoxycytidineDisease Models, AnimalDNA Mismatch RepairDrug Resistance, NeoplasmGemcitabineHumansImmune Checkpoint InhibitorsInterleukin-13Lymphocytes, Tumor-InfiltratingMiceB7-H1 AntigenCcl4 protein, mouseChemokine CCL4DeoxycytidineGemcitabineImmune Checkpoint InhibitorsInterleukin-13Mlh1 protein, mouseMutL Protein Homolog 1Tumor Necrosis Factor-alphacoding microsatellite mutationsgenetic modelimmune checkpoint inhibitorin vivo imagingMMR deficiencytumor microenvironment

Identifiers

PMID34206051
PMCPMC8199186
OpenAlexW3167180523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.